Evotec SE's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 145/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 5.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evotec SE's Score
Industry at a Glance
Industry Ranking
145 / 404
Overall Ranking
262 / 4562
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Hold
Current Rating
5.000
Target Price
+66.11%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Evotec SE Highlights
StrengthsRisks
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Overvalued
The company’s latest PE is -6.34, at a high 3-year percentile range.
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Ticker SymbolEVO
CompanyEvotec SE
CEOWojczewski (Christian)
Websitehttps://www.evotec.com/
FAQs
What is the current price of Evotec SE (EVO)?
The current price of Evotec SE (EVO) is 3.130.
What is the symbol of Evotec SE?
The ticker symbol of Evotec SE is EVO.
What is the 52-week high of Evotec SE?
The 52-week high of Evotec SE is 5.100.
What is the 52-week low of Evotec SE?
The 52-week low of Evotec SE is 2.840.
What is the market capitalization of Evotec SE?
The market capitalization of Evotec SE is 1.11B.
What is the net income of Evotec SE?
The net income of Evotec SE is -212.07M.
Is Evotec SE (EVO) currently rated as Buy, Hold, or Sell?
According to analysts, Evotec SE (EVO) has an overall rating of Hold, with a price target of 5.000.
What is the Earnings Per Share (EPS TTM) of Evotec SE (EVO)?
The Earnings Per Share (EPS TTM) of Evotec SE (EVO) is -0.493.